Ergun, MuslumSagir, Suleyman2025-05-152025-05-1520250004-06141576-8260https://doi.org/10.56434/j.arch.esp.urol.20257802.23https://hdl.handle.net/20.500.12514/8900Objective: This study aimed to investigate the effectiveness, safety and outcomes of the combination therapy of low-intensity extracorporeal shockwave therapy (Li-ESWT) and platelet-rich plasma (PRP) for the treatment of chronic-phase Peyronie's Methods: The clinical outcomes of patients diagnosed with Peyronie's disease and treated with Li-ESWT combined with PRP at our clinic between January 2018 and January 2024 were retrospectively reviewed and analysed. Twenty-three patients were excluded based on inclusion criteria, leaving 26 patients for the retrospective analysis. Each patient received three sessions of PRP and six sessions of Li-ESWT. The treatment regimen involved sessions administered twice weekly over a period of 3 weeks, followed by 1-week post-treatment follow-up. The patients were then monitored for 24 weeks. Result: After treatment, no significant reduction in average plaque size was observed. However, a statistically significant average improvement of 10 degrees was noted for penile curvature. Among the patients, 14 (53.8%) reported satisfaction with the treatment outcome, and 12 (46.2%) expressed dissatisfaction. No significant adverse effects were observed at the injection sites or in the areas subjected to Li-ESWT post-procedure. Conclusions: The combination of Li-ESWT and PRP is effective and safe for the treatment of chronic-phase Peyronie's disease.en10.56434/j.arch.esp.urol.20257802.23info:eu-repo/semantics/closedAccessPeyronie'S DiseasePenisExtracorporeal Shockwave TherapyPlatelet-Rich PlasmaArticle782164169Q4Q3WOS:0014626522000012-s2.0-10500192579040191859